Nomograms for predicting cervical central lymph node metastases and high-volume cervical central lymph node metastases in papillary thyroid carcinoma.

IF 1.5 3区 医学 Q3 SURGERY
Gland surgery Pub Date : 2025-03-31 Epub Date: 2025-03-26 DOI:10.21037/gs-24-237
Xindong Huang, Xiaoxiong Gan, Jianhua Feng, Wensong Cai, Bo Xu
{"title":"Nomograms for predicting cervical central lymph node metastases and high-volume cervical central lymph node metastases in papillary thyroid carcinoma.","authors":"Xindong Huang, Xiaoxiong Gan, Jianhua Feng, Wensong Cai, Bo Xu","doi":"10.21037/gs-24-237","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cervical central lymph node metastasis (CLNM) is a known risk factor for recurrent thyroid cancer (TC), and cervical high-volume central lymph node metastases (HVCLNM) are associated with higher recurrence rates and shorter disease-specific survival. The status of CLNM is critical in determining surgical strategies for papillary thyroid carcinoma (PTC). We developed two separate nomograms to predict the probability of CLNM and HVCLNM.</p><p><strong>Methods: </strong>We retrospectively analyzed 590 PTC patients who underwent total thyroidectomy or lobectomy with central lymph node dissection (CLND) between January 2020 and May 2023. Univariate and multivariate analyses were conducted to identify risk factors associated with CLNM and HVCLNM. The nomograms were internally validated using bootstrapping and evaluated on a temporal validation cohort.</p><p><strong>Results: </strong>Between January 2020 and May 2023, 1,019 patients were screened, 590 (57.9%) were eligible, and they were divided into development (n=353) and validation (n=237) cohorts. HVCLNM was present in 41 patients (11.6%). The variables with the strongest predictive value for CLNM were younger age (P<0.001), male sex (P=0.045), tumor size (P<0.001), and tumor multifocality (P=0.001). The strongest predictors for HVCLNM were younger age (P=0.001), tumor size (P<0.001), bilateral lesions (P=0.005), and preoperative serum thyroid peroxidase antibody (TPOAb) ≤14.95 IU/mL (P=0.01). The area under the curve (AUC) for the CLNM model was 0.75, with similar results achieved in internal validation (0.74) and external validation (0.68). The AUC for the HVCLNM model was 0.80, with similar values in internal validation (0.79) and external validation (0.79). Both models demonstrated good calibration, with predictions closely aligning with observed outcomes.</p><p><strong>Conclusions: </strong>Based on the quantified risk stratification offered by our nomograms, clinicians can engage in comprehensive preoperative discussions with PTC patients. Prophylactic CLND and strict postoperative evaluation may be recommended for patients with high nomogram scores.</p>","PeriodicalId":12760,"journal":{"name":"Gland surgery","volume":"14 3","pages":"421-435"},"PeriodicalIF":1.5000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12004298/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gland surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/gs-24-237","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Cervical central lymph node metastasis (CLNM) is a known risk factor for recurrent thyroid cancer (TC), and cervical high-volume central lymph node metastases (HVCLNM) are associated with higher recurrence rates and shorter disease-specific survival. The status of CLNM is critical in determining surgical strategies for papillary thyroid carcinoma (PTC). We developed two separate nomograms to predict the probability of CLNM and HVCLNM.

Methods: We retrospectively analyzed 590 PTC patients who underwent total thyroidectomy or lobectomy with central lymph node dissection (CLND) between January 2020 and May 2023. Univariate and multivariate analyses were conducted to identify risk factors associated with CLNM and HVCLNM. The nomograms were internally validated using bootstrapping and evaluated on a temporal validation cohort.

Results: Between January 2020 and May 2023, 1,019 patients were screened, 590 (57.9%) were eligible, and they were divided into development (n=353) and validation (n=237) cohorts. HVCLNM was present in 41 patients (11.6%). The variables with the strongest predictive value for CLNM were younger age (P<0.001), male sex (P=0.045), tumor size (P<0.001), and tumor multifocality (P=0.001). The strongest predictors for HVCLNM were younger age (P=0.001), tumor size (P<0.001), bilateral lesions (P=0.005), and preoperative serum thyroid peroxidase antibody (TPOAb) ≤14.95 IU/mL (P=0.01). The area under the curve (AUC) for the CLNM model was 0.75, with similar results achieved in internal validation (0.74) and external validation (0.68). The AUC for the HVCLNM model was 0.80, with similar values in internal validation (0.79) and external validation (0.79). Both models demonstrated good calibration, with predictions closely aligning with observed outcomes.

Conclusions: Based on the quantified risk stratification offered by our nomograms, clinicians can engage in comprehensive preoperative discussions with PTC patients. Prophylactic CLND and strict postoperative evaluation may be recommended for patients with high nomogram scores.

预测甲状腺乳头状癌颈淋巴中心淋巴结转移和大容量颈淋巴中心淋巴结转移的nomogram。
背景:宫颈中央淋巴结转移(CLNM)是复发性甲状腺癌(TC)的已知危险因素,宫颈高容量中央淋巴结转移(HVCLNM)与较高的复发率和较短的疾病特异性生存期相关。在确定甲状腺乳头状癌(PTC)的手术策略时,CLNM的状态是至关重要的。我们开发了两个独立的图来预测CLNM和HVCLNM的概率。方法:我们回顾性分析了2020年1月至2023年5月期间接受甲状腺全切除术或肺叶切除术合并中央淋巴结清扫(CLND)的590例PTC患者。进行单因素和多因素分析,以确定与CLNM和HVCLNM相关的危险因素。nomogram使用bootstrapping进行内部验证,并在时间验证队列上进行评估。结果:在2020年1月至2023年5月期间,筛选了1,019例患者,其中590例(57.9%)符合条件,他们被分为开发(n=353)和验证(n=237)队列。41例(11.6%)患者存在HVCLNM。结论:基于我们的nomographic提供的量化风险分层,临床医生可以与PTC患者进行全面的术前讨论。对于nomogram评分较高的患者,建议预防性CLND和严格的术后评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Gland surgery
Gland surgery Medicine-Surgery
CiteScore
3.60
自引率
0.00%
发文量
113
期刊介绍: Gland Surgery (Gland Surg; GS, Print ISSN 2227-684X; Online ISSN 2227-8575) being indexed by PubMed/PubMed Central, is an open access, peer-review journal launched at May of 2012, published bio-monthly since February 2015.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信